ANNOTATION

Liposomes are drug delivery systems with potential for the treatment of variety of diseases including cancer and a variety of liposomal formulations are already available on the market (e.g. Doxil®, DaunoXome®). However, these liposomes accumulate in the tumor only thanks to the enhanced permeability and retention effect. The specificity of the treatment can be increased by adding a targeting moiety, e.g. antibody, which specifically binds to the tumor cells. The aim of the work is to develop immunoliposomes – stealth liposomes with covalently attached antibodies or antibody fragments and study their stability, capability to encapsulate the active ingredient and ability to bind the tumor cells.